Jan 12, 2022 / 08:00PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good afternoon, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 40th JPMorgan Healthcare Conference today with Mersana. I'm joined by the company's CEO, Anna Protopapas, who's going to give a presentation on the business, and then we're going to go into some Q&A. (Operator Instructions) So with that, let me pass it over to Anna.
Anna Protopapas - Mersana Therapeutics, Inc. - President, CEO & Director
Thank you, Jess. Before I begin, let me just remind you that this presentation, I will be making forward-looking statements. So at Mersana, our vision is to become an ADC leader. And we have made substantial progress towards realizing this vision. There are 4 fundamental pillars to our strategy. First is to build UpRi, a lead asset into a foundational therapy in ovarian cancer. Based on a robust and compelling set of clinical proof-of-concept data, we're executing on a development strategy involving 3 studies: UPLIFT, UP-NEXT and
Mersana Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers